We are live on ! Find out more
CMMB

Chemomab Therapeutics
CMMB

17 hedge funds and large institutions have $4.07M invested in Chemomab Therapeutics in 2025 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

167% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 3

6% more funds holding

Funds holding: 16 → 17 (+1)

0.11% less ownership

Funds ownership: 0.36% → 0.25% (-0.11%)

46% less capital invested

Capital invested by funds: $7.53M → $4.07M (-$3.46M)

Holders
17
Holders Change
+1
Holders Change %
+6.25%
% of All Funds
0.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
8
Reduced
3
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TSS
Two Sigma Securities
New York
+$38.8K
2
VF
Virtu Financial
New York
+$28.7K
3
Morgan Stanley
Morgan Stanley
New York
+$22.4K
4
GI
GAMMA Investing
California
+$10.4K
5
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
+$7.01K

Top Sellers

Rank Fund Capital Flow
1
SFM
Sphera Funds Management
Israel
-$551K
2
YLHM
Yelin Lapidot Holdings Management
Israel
-$291K
3
XT
XTX Topco
Cayman Islands
-$20.4K

CMMB Hedge Fund Activity: Q1 2025 in Review

17 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Chemomab Therapeutics (CMMB) for Q1 2025, worth a combined $4.07M — down 46% from $7.53M a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new CMMB positions and 0 closed out — a net gain of 1 holder — while 8 added to existing stakes and 3 trimmed.

The largest buyer was Two Sigma Securities, opening a new position worth an estimated $38.8K. The largest seller was Sphera Funds Management, cutting an estimated $551K.

  • 17 institutional investors held Chemomab Therapeutics (CMMB) as of Q1 2025, up from 16 in Q4 2024.
  • Funds reported $4.07M of Chemomab Therapeutics stock for Q1 2025, down 46% quarter-over-quarter.
  • 1 fund opened new Chemomab Therapeutics positions in Q1 2025 and 0 closed out, a net change of +1 holder.
  • The largest Chemomab Therapeutics buyer in Q1 2025 was Two Sigma Securities, an estimated $38.8K added.
  • The largest Chemomab Therapeutics seller in Q1 2025 was Sphera Funds Management, an estimated $551K sold.

Based on aggregated 13F filings for Q1 2025.